Biblio
Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4(20):5311-5321.
. .
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020;4(15):3669-3676.
. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020;4(19):4812-4821.
.